Cytek will host a conference call to discuss its fourth quarter and year end 2024 financial results on Thursday, February 27, 2024, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. A webcast of the ...

Annexon Biosciences, Inc. ( ($ANNX) ) has released its Q4 earnings. Here is a breakdown of the information Annexon Biosciences, Inc. presented to ...

We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...

Solid Biosciences reported recent positive data in developing their gene therapy candidate SGT-003. The phase 1/2 INSPIRE ...

Feb. 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq ... “Cogent is preparing to report data from three bezuclastinib pivotal clinical trials this year,” said Andrew Robbins, ...

Reports Q4 revenue $ $201.27M ... Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences (HRMY). “This year will bring major milestones for Harmony, with the topline data ...

Research and Development (R&D) expenses: R&D expenses were $24.8 million for the fourth quarter of 2024, compared to $42.0 million for the fourth quarter of 2023. R&D expenses were $117.0 million for ...

Pacira (($PCRX)) has held its Q4 earnings call. Read on for the main highlights of the call. Pacira BioSciences’ recent earnings call painted a ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key functions of full-length dystrophin and allows it be delivered more effectively ...

CHARLESTOWN, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2024-financial-results ...